>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
脓毒症与凝血功能异常
作者:戴林峰  王醒 
单位:南京中医药大学 第一临床医学院, 江苏 南京 210029
关键词:脓毒症 凝血机制 凝血因子 文献综述 
分类号:R631
出版年·卷·期(页码):2012·31·第三期(359-362)
摘要:

凝血功能异常是急危重症患者常见的并发症。脓毒症时,组织因子诱导的外源性凝血途径激活,凝血机制增强,抗凝机制和纤溶系统受抑制,导致微循环血栓形成,器官微循环紊乱而加重器官功能障碍,与死亡率升高密切相关。多种炎症介质参与凝血机制的启动,在炎症过程中也经常有许多凝血蛋白的参与。作者以急危重症患者普遍存在凝血功能障碍为基础,探讨脓毒症时炎症反应和凝血机制之间的关系。

参考文献:

[1] LEVI M.Current understanding of disseminated intravascular coagulation[J].Br J Haematol,2004,124:567-576.
[2] ZEVERLEDER S,HACK C E,WILLEMIN W A.Disseminated intravascular coagulation in sepsis[J].Chest,2005,128:2864-2875.
[3] FOURRIER F,CHOPIN C,GOUDEMAND J,et al.Septic shock,multiple organ failure,and disseminated intravascular coagulation: Compared patterns of antithrombin Ⅲ,protein C,and protein S deficiencies[J].Chest,1992,101:816-823.
[4] MANN K G.Biochemistry and physiology of blood coagulation[J].Thromb Haemost,1999,82:165-174.
[5] LEVI M,de JONGE E,van der POLL T.Plasma and plasma components in the management of disseminated intravascular coagulation[J].Best Practice Res Clin Haematol,2006,19:127-142.
[6] FRANCO R F,de JONGE E,DEKKERS P E,et al.The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: relationship with activation of coagulation[J].Blood,2000,96:554-559.
[7] NEUMANN F J,MARX N,GAWAZ M,et al.Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets[J].Circulation,1997,95:2387-2394.
[8] AIRD W C.Vascular bed-specific hemostasis: role of endothelium in sepsis pathogenesis[J].Crit Care Med,2001,29:S28-S34.
[9] BROZE G J.Tissue factor pathway inhibitor and the revised theory of coagulation[J].Ann Rev Med,1995,46:103-112.
[10] de JONGE E,DEKKERS P E,CREASEY A A,et al.Tissue factor pathway inhibitor(TFPI) dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia[J].Blood,2000,95:1124-1129.
[11] HERMANS P W,HIBBERD M L,BOOY R,et al.4G/5G promoter polymorphism in the plasminogen-activator inhibitor-1 gene and outcome of meningococcal disease.Meningococcal Research Group[J].Lancet,1999,354:556-560.
[12] COUGHLIN S R.Thrombin signalling and protease-activated receptors[J].Nature,2000,407:258-264.
[13] REZAIE A R.Regulation of the protein C anticoagulant and antinflammatory pathways[J].Curr Med Chem,2010,17:2059-2069.
[14] ABRAHAM E,REINHART K,SVOBODA P,et al.Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter,randomized,placebo-controlled,single-blind,dose escalation study[J].Crit Care Med,2001,29: 2081- 2089.
[15] ABRAHAM E,REINHART K,OPAL S,et al.Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial[J].JAMA,2003,290:238-247.
[16] WARREN B L,EID A,SINGER P,et al.Caring for the critically ill patient High-dose antithrombin Ⅲ in severe sepsis: a randomized controlled trial[J].JAMA,2001,286:1869-1878.
[17] WIEDERMANN C J,KANEIDER N C.A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis[J].Blood Coagul Fibrinol,2006,17:521- 526.
[18] GROSS S J,FILSTON H C,ANDERSON J C.Controlled study of treatment for disseminated intravascular coagulation in the neonate[J].J Pediatr,1982,100:445-448.
[19] BERNARD G R,VINCENT J L,LATERRE P F,et al.For the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group.Efficacy and safety of recombinant human activated protein C for severe sepsis[J].N Engl J Med,2001,344: 699-709.
[20] BERNARD G R,ELY E W,WRIGHT T J,et al.Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis[J].Crit Care Med,2001,29:2051-2059.
[21] DHAINAUT J F,YAN S B,JOYCE D E,et al.Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation[J].J Thromb Haemost,2004,2(11):1924-1933.
[22] VINCENT J L,ANGUS D C,ARTIGAS A,et al.Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial[J].Crit Care Med,2003,31:834-840.
[23] LEVI M.Benefit of recombinant human activated protein C beyond 28-day mortality:there is more to life than death[J].Crit Care Med,2003,31:984-985.
[24] MARTÍ-CARVAJAL A J,SOLÀ I,LATHYRIS D,et al.Human recombinant activated protein C for severe sepsis[J].Cochrane Database Syst Rev,2011,13(4):CD004388.
[25] SILVA E,de FIGUEIREDO L F,COLOMBARI F.Prowess-shock trial: a protocol overview and perspectives[J].Shock,2010,34:48-53.
[26] de KLEIJN E D,de GROOT R,HACK C E,et al.Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans:a randomized,double-blinded,placebo-controlled,dose-finding study[J].Crit Care Med,2003,31:1839-1847.
[27] MIKKELSEN M E,MILTIADES A N,GAIESKI D F,et al.Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock[J].Crit Care Med,2009,37:1670-1677.
[28] YANG C S,QIU H B,HUANG Y Z,et al.Prospective research on the prognosis of septic shock based on the change of lactate concentration in arterial blood[J].Zhonghua Wai Ke Za Zhi,2009,47:685-688.
[29] SEEAR M D,SCARFE J C,LEBLANC J G.Predicting major adverse events after cardiac surgery in children[J].Pediatr Crit Care Med,2008,9:606-611.
[30] BASARAN M,SEVER K,KAFALI E,et al.Serum lactate level has prognostic significance after pediatric cardiac surgery[J].J Cardiothorac Vasc Anesth,2006,20:43-47.
[31] MAILLET J M,le BESNERAIS P,CANTONI M,et al.Frequency,risk factors,and outcome of hyperlactatemia after cardiac surgery[J].Chest,2003,123:1361-1366.
[32] RADY M Y,RIVERS E P,MARTIN G B,et al.Continuous central venous oximetry and shock index in the emergency department:use in the evaluatio of clinical shock[J].Am J Emerg Med,1992,10:538-541.
[33] KLIEGEL A,LOSERT H,STERZ F,et al.Serial lactate determinations for prediction of outcome after cardiac arrest[J].Medicine (Baltimore),2004,83:274-279.
[34] ABRAMSON D,SCALEA T M,HITCHCOCK R,et al.Lactate clearance and survival following injury[J].J Trauma,1993,35:584-589.
[35] MCNELIS J,MARINI C P,JURKIEWICZ A,et al.Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit[J].Am J Surg,2001,182:481-485.
[36] WATANABE I,MAYUMI T,ARISHIMA T,et al.Hyperlactemia can predict the prognosis of liver resection[J].Shock,2007,28:35-38.
[37] ANTONELLI M,LEVY M,ANDREWS P J,et al.Hemodynamic monitoring in shock and implications for management[J].Intensive Care Med,2007,33:575-590.
[38] ADUEN J,BERNSTEIN W K,KHASTGIR T,et al.The use and clinical importance of a substrate-specific electrode for rapid determination of blood lactate concentrations[J].JAMA,1994,272:1678-1685.
[39] LEVY M M,MACIAS W L,VINCENT J L,et al.Early changes in organ function predict eventual survival in severe sepsis[J].Crit Care Med,2005,33:2194-2201.
[40] de BACKER D,VERDANT C,CHIEREGO M,et al.Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis[J].Crit Care Med,2006,34:1918-1924.
[41] SHREENIWAS R,KOGA S,KARAKURUM M,et al.Hypoxia-mediated induction of endothelial cell interleukin-1 alpha.An autocrine mechanism promoting expression of leukocyte adhesion molecules on the vessel surface[J].J Clin Invest,1992,90:2333-2339.
[42] YAN S F,TRITTO I,PINSKY D,et al.Induction of interleukin 6 (IL-6) by hypoxia in vascular cells,Central role of the binding site for nuclear factor-IL-6[J].J Biol Chem,1995,270:11463-11471.
[43] KARAKURUM M,SHREENIWAS R,CHEN J,et al.Hypoxic induction of interleukin-8 gene expression in human endothelial cells[J].J Clin Invest,1994,93:1564-1570.
[44] LEEPER-WOODFORD S K,FISHER B J,SUGERMAN H J,et al.Pharmacologic reduction in tumor necrosis factor activity of pulmonary alveolar macrophages[J].Am J Respir Cell Mol Biol,1993,8:169-175.
[45] GHEZZI P,DINARELLO C A,BIANCHI M,et al.Hypoxia increases production of interleukin-1 and tumor necrosis factor by human mononuclear cells[J].Cytokine,1991,3:189-194.
[46] TODA K,KAYANO K,KARIMOVA A,et al.Antisense intercellular adhesion molecule-1 (ICAM-1) oligodeoxyribonucleotide delivered during organ preservation inhibits posttransplant ICAM-1 expression and reduces primary lung isograft failure[J].Circ Res,2000,86:166-174.
[47] WANG C Y,NAKA Y,LIAO H,et al.Cardiac graft intercellular adhesion molecule-1 (ICAM-1) and interleukin-1 expression mediate primary isograft failure and induction of ICAM-1 in organs remote from the site of transplantation[J].Circ Res,1998,82:762-772.
[48] IVEY C L,WILLIAMS F M,COLLINS P D,et al.Neutrophil chemoattractants generated in two phases during reperfusion of ischemic myocardium in the rabbit,Evidence for a role for C5a and interleukin-8[J].J Clin Invest,1995,95:2720-2728.
[49] PHUA J,KOAY E S,LEE K H.Lactate,procalcitonin,and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock[J].Shock,2008,29:328-333.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 405818 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-83272481 83272483
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364